Model structure and control of bone remodeling: A theoretical study

Bone

Volumn 43, Issue 2, 2008, Pages 249-263

  Pivonka, Peter ^a   Zimak, Jan ^a   Smith, David W ^a   Gardiner, Bruce S ^a   Dunstan, Colin R ^b   Sims, Natalie A ^a   Martin, T John ^a   Mundy, Gregory R ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ANZAC RESEARCH INSTITUTE   (Australia)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Bone remodeling; Cell population dynamics; Model structure and control of bone remodeling; Osteoblast osteoclast interactions; TGF

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTICLE; BONE; BONE CELL; BONE MATRIX; BONE REMODELING; CATABOLISM; CELL DIFFERENTIATION; CELL POPULATION; CELL TYPE; HORMONE ACTION; MATHEMATICAL MODEL; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STEM CELL; THEORETICAL MODEL; THEORETICAL STUDY; ANIMAL; BIOLOGICAL MODEL; CYTOLOGY; HUMAN; METABOLISM; ORGAN SIZE;

ANIMALS; APOPTOSIS; BONE REMODELING; HUMANS; MODELS, BIOLOGICAL; ORGAN SIZE; OSTEOBLASTS; OSTEOPROTEGERIN; RANK LIGAND;

EID: 52449126861     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.03.025     Document Type: Article

References (44)

1. Lemaire V, Tobin FL, Greller LD, Cho CR, Suva LJ. Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. J Theor Biol 2004;229: 293-309.
2. Mundy GR. Cellular andmolecular regulation of bone turnover. Bone 1999;24:35S-8S.
3. Parfitt AM. Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. Bone 2002;30:5-7.
4. Martin RB. Is all cortical bone remodeling initiated by microdamage? Bone 2002;30:8-13.
5. Burr DB. Targeted and nontargeted remodeling. Bone 2002;30:2-4.
6. Martin GR, Burr DB, Sharkey NA. Skeletal tissue mechanics. New York, USA: Springer; 1998.
7. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289:1508-14.
8. Aubin JE. Advances in the osteoblast lineage. Biochem Cell Biol 1998;76:899-910.
9. Aubin JE. Bone stem cells. J Cell Biochem Sublements 1998;30:73-82.
10. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504.
11. Martin TJ. Paracrine regulation of osteoclast formation and activity: milestones in discovery. J Musculoskelet Neuronal Interact 2004;4:243-53.
12. Hofbauer LC, Kuehne CA, Viereck V. The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 2004;4:268-75.
13. Robling RB, Castillo AB, Turner CH. Biomechanical and molecular regulation of bone remodeling. Annu Rev Biomed Eng 2006;8:6.1-6.44.
14. Defranoux NA, Stokes CL, Young DL, Kahn AJ. In silico modeling and simulation of bone biology: a proposal. J Bone Miner Res 2005;20:1079-84.
15. Ventura BD, Lemerle C, Michalodimitrakis K, Serrano L. From in vivo to in silico biology and back. Nature 2006;443:527-33.
16. Kroll MH. Parathyroid hormone temporal effects on bone formation and resorption. Bull Math Biol 2000;62:163-88.
17. Rattanakul C, Lenbury Y, Krishnamara N, Wollkind DJ. Modeling of bone formation and resorption mediated by parathyroid hormone: response to estrogen/PTH therapy. Biosystems 2003;70:55-72.
18. Komarova SV. Mathematical model of paracrine interactions between osteoclasts and osteoblasts predicts anabolic action of parathyroid hormone on bone. Endocrinology 2005;146:3589-95.
19. Komarova SV, Smith RJ, Dixon SJ, Sims SM, Wahl LM. Mathematical model predicts a critical role for osteoclast autocrine regulation in the control of bone remodeling. Bone 2003;33:206-15.
20. Savageau MA. Biochemical systems analysis - a study of function and design in molecular biology. Massachusetts, USA: Addison-Wesley Pub. Co.; 1976.
21. Janssens K, ten Dijke P, Janssens S, Van Hul W. Transforming growth factor-beta1 to the bone. Endocr Rev 2005;26:743-74.
22. Mundy GR. Bone remodeling and its disorders. 2nd ed. London, England: Martin Dunitz Ltd; 1999.
23. Roodman GD. Cell biology of the osteoclast. Exp Hematol 1999;27:1229-41.
24. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337.
25. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
26. Bell NH. RANKL and the regulation of skeletal remodeling. J Clin Invest 2003;111:1120-2.
27. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12.
28. Hofbauer LC, Neubauer A, Heufelder AE. Receptor activator of nuclear factor-$\ka\be$ ligand and osteoprotegrin. Cancer 2001;92:460-70.
29. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004;292:490-5.
30. Cohen MM. Transforming growth factor beta's and fibroblast growth factors and their receptors: role in sutural biology and craniosynostosis. J Bone Miner Res 1997;12:322-31.
31. Bonewald LF, Dallas SL. Role of active and latent transforming growth factor beta in bone formation. J Cell Biochem Sublements 1994;55:350-7.
32. Seyedin SM, Thomas TC, Thompson AY, Rosen DM, Piez KA. Purification and characterization of two cartilage-inducing factors from bovine demineralized bone. PNAS 1985;82:2267-71.
33. Hauschka P, Mavrakos A, Iafrati M, Doleman S, Klagsbrun M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparinsepharose. J Biol Chem 1986;261:12665-74.
34. Erlebacher A, Filvaroff EH, Ye JQ, Derynck R. Osteoblastic responses to TGF-beta during bone remodeling. Mol Biol Cell 1998;9:1903-18.
35. Fuller K, Lean J, Bayley K, Wani M, Chambers T. A role for TGFbeta(1) in osteoclast differentiation and survival. J Cell Sci 2000;113:2445-53.
36. Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 2000;141:4768-76.
37. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 1998;250:776-81.
38. Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K, et al. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor. Bone 1999;25:517-23.
39. Lauffenburger DA, Linderman JJ. Receptors: models for binding, trafficking, and signaling. New York, USA: Oxford University Press; 1993.
40. Alon U. An introduction to systems biology: design principles of biological circuits. New York, USA: Chapman and Hall; 2007.
41. Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 2005;20:177-84.
42. Glass II DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005;8:751-64.
43. Thomas G, Baker S, Eisman J, Gardiner E. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. J Endocrinol 2001;170:451-60.
44. Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, et al. PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 2004;19: 235-44.